ALP Life Sciences, LLC Announces Nanoveson(TM) Patent Filing and Whitepaper Availability on Proposed Therapy for Non-Alcoholic Fatty Liver Disease (NAFLD) and Comorbi...(here is extensive research focused on bl...),Health

Date:6/24/2009

here is extensive research focused on blocking arachidonic acid metabolism along cytochrome P450, leukotriene, prostaglandin, and thromboxane eicosanoid pathways. Arachidonic acid metabolism is implicated in many inflammatory diseases, including cardiovascular diseases, gastrointestinal diseases, arthritis, asthma, diabetes and cancer. Nanoveson(TM) therapy may improve enterohepatic circulation by removing excess triglyceride deposits in the liver and improving bile flow; having a positive therapeutic impact on arachidonic acid driven disease states by reducing arachidonic acid availability for inflammatory metabolism. Orphan disease indication targets for inflammatory diseases may be pursed through clinical trials focused on arachidonic acid specific surrogate end points.

David K. Barker, Founder and CEO of ALP Life Sciences, LLC stated, "The preliminary evidence for the Nanoveson(TM) hypotheses is very promising, however, it should be emphasized that the complex mechanisms of action triggered by Nanoveson(TM) must be quantified, and the efficacy for targeted indications must be established by clinical trials." Barker added, "I'd like to take this opportunity to acknowledge the many scientists and physicians referenced in the Nanoveson(TM) whitepaper. Without their dedication to medical research the preliminary research and hypotheses presented in the Nanoveson(TM) whitepaper would not have been possible. However, nothing in this release or in the whitepaper suggests referenced researchers endorse the preliminary conclusions presented at this time."

ALP Life Sciences, LLC is a life sciences research and development company focused on therapeutics and diagnostics based on the new and emerging science of Applied Lipid Polymorphism. ALP Life Sciences, LLC is currently evaluating strategic relationships in the area of principal investigators, clinical trial facilities, medical school research partnerships, manufacturing,
'/>"/>

SOURCE ALP Life Sciences, LLC Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3
Related medicine technology :

1. Dow AgroSciences, World Wide Wheat Agree to Collaborate on Wheat
2. Intellect Neurosciences, Inc. Announces Independent Studies on Copper Binding Properties of its Lead Candidate OXIGON(TM)
3. Pressure BioSciences, Inc. Announces $850,000 NIH SBIR Phase II Award for the Development of a New PCT-dependent System for Improved Biomarker Discovery, Diagnostics, and Drug Discovery
4. Intellect Neurosciences, Inc. and Medical Research Council Technology (U.K.) Reach Important Milestone in Generating an Alzheimers Therapeutic Antibody
5. Novel PCT Method Unveiled by Pressure BioSciences, Inc. and Collaborators at the Harvard School of Public Health
6. Ardea Biosciences, Inc. Announces New Clinical Development Program Directed Toward the Treatment of Gout
7. Intellect Neurosciences, Inc. and CHDI, Inc. Enter Into Compound Testing Agreement to Evaluate OXIGON(TM) as a Potential Treatment for Huntington Disease
8. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
9. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
10. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
11. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference